Paliperidon Ratiopharm (Paliperidone Palmitate)

Paliperidone palmitate, the active ingredient in Paliperidon Ratioph., is an antipsychotic presented as a long‑acting injectable suspension for intramuscular use. It is employed in the maintenance treatment of schizophrenia in adult patients. GNH USA supplies Paliperidon Ratioph. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Paliperidon Ratioph. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Paliperidone palmitate is an atypical antipsychotic used in the management of schizophrenia and related psychotic disorders.

- Schizophrenia: helps maintain symptom control and reduces risk of relapse when given as a monthly injection. - Schizoaffective disorder: contributes to stabilization of mood and psychotic symptoms. - Bipolar I disorder (maintenance): used as an adjunct to mood stabilisers to prevent manic or depressive episodes. - Acute psychotic episodes (adjunct): may be added to oral therapy to achieve faster symptom control. - Long‑term maintenance therapy: provides consistent plasma levels, improving adherence. - Relapse prevention: reduces hospital readmission rates in stabilized patients.

Paliperidone palmitate may cause a range of adverse reactions, most of which are dose‑dependent and often resolve with continued therapy.

Common Side Effects: - Injection site pain or erythema - Headache - Drowsiness or somnolence - Weight gain - Restlessness (akathisia) - Constipation

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Tardive dyskinesia - Severe orthostatic hypotension - Hyperglycaemia or new‑onset diabetes - Seizures - Elevated prolactin with galactorrhoea or menstrual disturbances

When prescribing Paliperidone palmitate, clinicians should consider several safety aspects.

- Cardiovascular assessment: evaluate for history of arrhythmias or QT prolongation. - Metabolic monitoring: check weight, glucose and lipid profiles regularly. - Neurological review: watch for early signs of extrapyramidal symptoms. - Pregnancy and lactation: avoid use unless benefits clearly outweigh risks. - Elderly patients: start at lower doses and monitor for sedation and falls. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Paliperidone palmitate can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, rifampicin): may reduce plasma concentrations. - Potent alpha‑adrenergic antagonists: increase risk of orthostatic hypotension.

Moderate Interactions (Monitor Closely):\n- Other antipsychotics: additive extrapyramidal effects. - CNS depressants (e.g., benzodiazepines, opioids): enhanced sedation. - Antihistamines with anticholinergic activity: may worsen dry mouth and constipation. - QT‑prolonging agents: monitor ECG for additive cardiac effects. - Lithium: increased risk of neurotoxicity. - Antidiabetic drugs: monitor glucose as paliperidone may affect glycaemic control.